Core Insights - The Chinese pharmaceutical industry is transitioning from "generic following" to "innovation leading," with 704 original innovative drugs expected from Chinese companies in 2024, ranking first globally [2] - The chairman of Dongyang Sunshine Pharmaceutical, Zhang Yingjun, emphasizes that the industry is entering a "golden decade" driven by innovation and internationalization, supported by favorable policies [2][3] - Dongyang Sunshine is focusing on source innovation, with a diverse R&D pipeline that includes small molecules, antibodies, small nucleic acids, ADCs, and cell therapies [2][3] Industry Trends - The Chinese pharmaceutical sector is experiencing a strategic opportunity period centered on innovation and internationalization, as highlighted by Zhang Yingjun at the 2025 Greater Bay Area Technology and Financial Innovation Development Conference [2] - The industry is benefiting from a supportive policy environment, including integration into ICH and continuous inclusion of innovative drugs in government work reports [2] Company Strategy - Dongyang Sunshine has shifted its R&D strategy from "Me-too" and "Fast-follow" to pursuing "BIC" (Best-in-Class) and "FIC" (First-in-Class) drugs [2] - The company currently has nearly 50 projects in the pipeline, with over 10 in registration or key clinical stages, showcasing differentiated advantages and international competitiveness [2] Technological Innovation - The company is leveraging AI technology, having developed six AI models for drug discovery, with its first AI-driven small molecule drug, HEC169584, entering clinical trials [3] - Dongyang Sunshine has established multiple core technology platforms to address significant unmet clinical needs, such as solid tumor treatment and hepatitis B cure [3] Internationalization Efforts - The internationalization strategy of Dongyang Sunshine is multifaceted, involving "License-out" agreements and plans for self-marketing products in Europe and the U.S. [3] - The company aims to have its insulin product approved in the U.S. by Q1 2026, potentially becoming the first domestically produced insulin to enter the U.S. market [3] Future Goals - Dongyang Sunshine aims to become a leading comprehensive pharmaceutical company focused on "innovation + internationalization + sustainability," targeting over 20 billion yuan in revenue and 5 billion yuan in profit within five years [4] - The company plans to launch over 10 new products and achieve more than five global collaborations in the same timeframe [4] Industry Perspective - Zhang Yingjun states that the advancement of Chinese pharmaceutical companies is fundamentally about the global recognition and validation of innovative value [5] - The company is actively participating in and leading this historic process through its dual focus on innovation and internationalization [5]